Skip to main content

Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.

Publication ,  Journal Article
Thompson, GR; Jenks, JD; Baddley, JW; Lewis, JS; Egger, M; Schwartz, IS; Boyer, J; Patterson, TF; Chen, SC-A; Pappas, PG; Hoenigl, M
Published in: Clin Microbiol Rev
September 21, 2023

Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated with high morbidity and mortality (>70%), and presents numerous challenges during clinical care. Candida spp. are the most common causes of fungal endocarditis, implicated in over 50% of cases, followed by Aspergillus and Histoplasma spp. Important risk factors for fungal endocarditis include prosthetic valves, prior heart surgery, and injection drug use. The signs and symptoms of fungal endocarditis are nonspecific, and a high degree of clinical suspicion coupled with the judicious use of diagnostic tests is required for diagnosis. In addition to microbiological diagnostics (e.g., blood culture for Candida spp. or galactomannan testing and PCR for Aspergillus spp.), echocardiography remains critical for evaluation of potential infective endocarditis, although radionuclide imaging modalities such as 18F-fluorodeoxyglucose positron emission tomography/computed tomography are increasingly being used. A multimodal treatment approach is necessary: surgery is usually required and should be accompanied by long-term systemic antifungal therapy, such as echinocandin therapy for Candida endocarditis or voriconazole therapy for Aspergillus endocarditis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Microbiol Rev

DOI

EISSN

1098-6618

Publication Date

September 21, 2023

Volume

36

Issue

3

Start / End Page

e0001923

Location

United States

Related Subject Headings

  • Mycoses
  • Microbiology
  • Humans
  • Endocarditis, Bacterial
  • Endocarditis
  • Candidiasis
  • Candida
  • Aspergillus
  • Antifungal Agents
  • 3207 Medical microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, G. R., Jenks, J. D., Baddley, J. W., Lewis, J. S., Egger, M., Schwartz, I. S., … Hoenigl, M. (2023). Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. Clin Microbiol Rev, 36(3), e0001923. https://doi.org/10.1128/cmr.00019-23
Thompson, George R., Jeffrey D. Jenks, John W. Baddley, James S. Lewis, Matthias Egger, Ilan S. Schwartz, Johannes Boyer, et al. “Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.Clin Microbiol Rev 36, no. 3 (September 21, 2023): e0001923. https://doi.org/10.1128/cmr.00019-23.
Thompson GR, Jenks JD, Baddley JW, Lewis JS, Egger M, Schwartz IS, et al. Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. Clin Microbiol Rev. 2023 Sep 21;36(3):e0001923.
Thompson, George R., et al. “Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.Clin Microbiol Rev, vol. 36, no. 3, Sept. 2023, p. e0001923. Pubmed, doi:10.1128/cmr.00019-23.
Thompson GR, Jenks JD, Baddley JW, Lewis JS, Egger M, Schwartz IS, Boyer J, Patterson TF, Chen SC-A, Pappas PG, Hoenigl M. Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. Clin Microbiol Rev. 2023 Sep 21;36(3):e0001923.

Published In

Clin Microbiol Rev

DOI

EISSN

1098-6618

Publication Date

September 21, 2023

Volume

36

Issue

3

Start / End Page

e0001923

Location

United States

Related Subject Headings

  • Mycoses
  • Microbiology
  • Humans
  • Endocarditis, Bacterial
  • Endocarditis
  • Candidiasis
  • Candida
  • Aspergillus
  • Antifungal Agents
  • 3207 Medical microbiology